132 related articles for article (PubMed ID: 28957959)
1. Is There a Relationship Between Patient-Reported Satisfaction and Persistence on Overactive Bladder Syndrome Pharmacotherapy?
Tran AM; Reis R; Iyer S; Botros C; Goldberg RP; Sand PK; Botros SM
Female Pelvic Med Reconstr Surg; 2018; 24(3):237-240. PubMed ID: 28957959
[TBL] [Abstract][Full Text] [Related]
2. Interventions do not enhance medication persistence and compliance in patients with overactive bladder: a 24 weeks, randomised, open-label, multi-center trial.
Sung HH; Han DH; Kim TH; Lee YS; Lee HN; Seo JT; Choo MS; Lee KS
Int J Clin Pract; 2015 Nov; 69(11):1309-15. PubMed ID: 26215431
[TBL] [Abstract][Full Text] [Related]
3. Does physician specialty affect persistence to pharmacotherapy among patients with overactive bladder syndrome?
Tran AM; Sand PK; Seitz MJ; Gafni-Kane A; Zhou Y; Botros SM
Int Urogynecol J; 2017 Mar; 28(3):409-415. PubMed ID: 27539566
[TBL] [Abstract][Full Text] [Related]
4. Persistence with prescribed antimuscarinic therapy for overactive bladder: a UK experience.
Wagg A; Compion G; Fahey A; Siddiqui E
BJU Int; 2012 Dec; 110(11):1767-74. PubMed ID: 22409769
[TBL] [Abstract][Full Text] [Related]
5. Persistence and adherence with mirabegron vs antimuscarinics in overactive bladder: Retrospective analysis of a UK General Practice prescription database.
Wagg AS; Foley S; Peters J; Nazir J; Kool-Houweling L; Scrine L
Int J Clin Pract; 2017 Oct; 71(10):. PubMed ID: 28906080
[TBL] [Abstract][Full Text] [Related]
6. Persistence with mirabegron therapy for overactive bladder: A real life experience.
Pindoria N; Malde S; Nowers J; Taylor C; Kelleher C; Sahai A
Neurourol Urodyn; 2017 Feb; 36(2):404-408. PubMed ID: 26669282
[TBL] [Abstract][Full Text] [Related]
7. Persistence and Adherence with Mirabegron versus Antimuscarinic Agents in Patients with Overactive Bladder: A Retrospective Observational Study in UK Clinical Practice.
Chapple CR; Nazir J; Hakimi Z; Bowditch S; Fatoye F; Guelfucci F; Khemiri A; Siddiqui E; Wagg A
Eur Urol; 2017 Sep; 72(3):389-399. PubMed ID: 28196724
[TBL] [Abstract][Full Text] [Related]
8. Predictors of discontinuing overactive bladder medications.
Brubaker L; Fanning K; Goldberg EL; Benner JS; Trocio JN; Bavendam T; Jumadilova Z
BJU Int; 2010 May; 105(9):1283-90. PubMed ID: 19912189
[TBL] [Abstract][Full Text] [Related]
9. Patient-reported outcomes in patients with overactive bladder treated with mirabegron and tolterodine in a prospective, double-blind, randomized, two-period crossover, multicenter study (PREFER).
Herschorn S; Staskin D; Tu LM; Fialkov J; Walsh T; Gooch K; Schermer CR
Health Qual Life Outcomes; 2018 Apr; 16(1):69. PubMed ID: 29673355
[TBL] [Abstract][Full Text] [Related]
10. A retrospective study of treatment persistence and adherence to mirabegron versus antimuscarinics, for the treatment of overactive bladder in Spain.
Nazir J; Hakimi Z; Guelfucci F; Khemiri A; Fatoye F; Blázquez AMM; González MH
BMC Urol; 2018 Sep; 18(1):76. PubMed ID: 30180826
[TBL] [Abstract][Full Text] [Related]
11. Long-term patterns of use and treatment failure with anticholinergic agents for overactive bladder.
Chancellor MB; Migliaccio-Walle K; Bramley TJ; Chaudhari SL; Corbell C; Globe D
Clin Ther; 2013 Nov; 35(11):1744-51. PubMed ID: 24091072
[TBL] [Abstract][Full Text] [Related]
12. [Degree of satisfaction of patients continuing overactive bladder treatment with mirabegron].
Švabík K; Mašata J; Krhut J; Zachoval R; Hanuš T; Halaška M; Horčička L; Krofta L; Hanáková M; Martan A
Ceska Gynekol; 2017; 82(1):48-52. PubMed ID: 28252310
[TBL] [Abstract][Full Text] [Related]
13. Persistence with first line anticholinergic medication in treatment-naïve overactive bladder patients.
Krhut J; Gärtner M; Petzel M; Sykora R; Nemec D; Tvrdik J; Skoupa J
Scand J Urol; 2014 Feb; 48(1):79-83. PubMed ID: 23870042
[TBL] [Abstract][Full Text] [Related]
14. Patient satisfaction with extended release tolterodine or oxybutynin in overactive bladder.
Bolge SC; McDonnell DD; Chen A; Wan GJ
Curr Med Res Opin; 2007 Aug; 23(8):1903-12. PubMed ID: 17610806
[TBL] [Abstract][Full Text] [Related]
15. Comparative persistence and adherence to overactive bladder medications in patients with and without diabetes.
Johnston S; Janning SW; Haas GP; Wilson KL; Smith DM; Reckard G; Quan SP; Bukofzer S
Int J Clin Pract; 2012 Nov; 66(11):1042-51. PubMed ID: 23067028
[TBL] [Abstract][Full Text] [Related]
16. Combined effects of behavioral intervention and tolterodine in patients dissatisfied with overactive bladder medication.
Klutke CG; Burgio KL; Wyman JF; Guan Z; Sun F; Berriman S; Bavendam T
J Urol; 2009 Jun; 181(6):2599-607. PubMed ID: 19375110
[TBL] [Abstract][Full Text] [Related]
17. Healthcare resource use and costs of privately insured patients who switch, discontinue, or persist on anti-muscarinic therapy for overactive bladder.
Ivanova JI; Hayes-Larson E; Sorg RA; Birnbaum HG; Berner T
J Med Econ; 2014 Oct; 17(10):741-50. PubMed ID: 25051328
[TBL] [Abstract][Full Text] [Related]
18. Drug persistence and compliance affect patient-reported outcomes in overactive bladder syndrome.
Kim TH; Choo MS; Kim YJ; Koh H; Lee KS
Qual Life Res; 2016 Aug; 25(8):2021-9. PubMed ID: 26701707
[TBL] [Abstract][Full Text] [Related]
19. Persistence and compliance with medication management in the treatment of overactive bladder.
Kim TH; Lee KS
Investig Clin Urol; 2016 Mar; 57(2):84-93. PubMed ID: 26981589
[TBL] [Abstract][Full Text] [Related]
20. Darifenacin treatment for overactive bladder in patients who expressed dissatisfaction with prior extended-release antimuscarinic therapy.
Zinner N; Kobashi KC; Ebinger U; Viegas A; Egermark M; Quebe-Fehling E; Koochaki P
Int J Clin Pract; 2008 Nov; 62(11):1664-74. PubMed ID: 18811599
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
